Year: 2024
Type: article
Abstract: It is recommended that Cabtreo be reimbursed by public drug plans for the topical treatment of acne vulgaris in patients 12 years of age and older if certain conditions are met. Cabtreo should only be covered to treat patients 12 years of age and older with acne vulgaris. Cabtreo should only be reimbursed if the price of Cabtreo is negotiated so that it does not exceed the drug program cost of treatment with topical therapy for acne vulgaris reimbursed by participating plans.
Author: CDA-AMC
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4404110653